Literature DB >> 19918243

1H-MRS at 4 tesla in minimally treated early schizophrenia.

J R Bustillo1, L M Rowland, P Mullins, R Jung, H Chen, C Qualls, R Hammond, W M Brooks, J Lauriello.   

Abstract

We investigated glutamate-related neuronal dysfunction in the anterior cingulate (AC) early in schizophrenia before and after antipsychotic treatment. A total of 14 minimally treated schizophrenia patients and 10 healthy subjects were studied with single-voxel proton magnetic resonance spectroscopy ((1)H-MRS) of the AC, frontal white matter and thalamus at 4 T. Concentrations of N-acetylaspartate (NAA), glutamate (Glu), glutamine (Gln) and Gln/Glu ratios were determined and corrected for the partial tissue volume. Patients were treated with antipsychotic medication following a specific algorithm and (1)H-MRS was repeated after 1, 6 and 12 months. There were group x region interactions for baseline NAA (P=0.074) and Gln/Glu (P=0.028): schizophrenia subjects had lower NAA (P=0.045) and higher Gln/Glu (P=0.006) in the AC before treatment. In addition, AC Gln/Glu was inversely related to AC NAA in the schizophrenia (P=0.0009) but not in the control group (P=0.92). Following antipsychotic treatment, there were no further changes in NAA, Gln/Glu or any of the other metabolites in any of the regions studied. We conclude that early in the illness, schizophrenia patients already show abnormalities in glutamatergic metabolism and reductions in NAA consistent with glutamate-related excitotoxicity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19918243      PMCID: PMC2892215          DOI: 10.1038/mp.2009.121

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  37 in total

1.  Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia.

Authors:  L A Glantz; D A Lewis
Journal:  Arch Gen Psychiatry       Date:  2000-01

2.  Subchronic phencyclidine treatment decreases the number of dendritic spine synapses in the rat prefrontal cortex.

Authors:  Tibor Hajszan; Csaba Leranth; Robert H Roth
Journal:  Biol Psychiatry       Date:  2006-06-30       Impact factor: 13.382

3.  Long-term treatment of rats with haloperidol: lack of an effect on brain N-acetyl aspartate levels.

Authors:  Juan Bustillo; Ranee Barrow; Rodrigo Paz; Jennifer Tang; Navid Seraji-Bozorgzad; Gregory J Moore; Federico Bolognani; John Lauriello; Nora Perrone-Bizzozero; Matthew P Galloway
Journal:  Neuropsychopharmacology       Date:  2006-04       Impact factor: 7.853

Review 4.  Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis.

Authors:  R Grant Steen; Robert M Hamer; Jeffrey A Lieberman
Journal:  Neuropsychopharmacology       Date:  2005-11       Impact factor: 7.853

5.  Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat.

Authors:  Xavier López-Gil; Zoila Babot; Mercè Amargós-Bosch; Cristina Suñol; Francesc Artigas; Albert Adell
Journal:  Neuropsychopharmacology       Date:  2007-03-14       Impact factor: 7.853

Review 6.  Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging.

Authors:  P J Magistretti; L Pellerin
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-07-29       Impact factor: 6.237

7.  Brain gray and white matter transverse relaxation time in schizophrenia.

Authors:  A Pfefferbaum; E V Sullivan; M Hedehus; M Moseley; K O Lim
Journal:  Psychiatry Res       Date:  1999-08-31       Impact factor: 3.222

8.  Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia.

Authors:  Juan R Bustillo; Laura M Rowland; Rex Jung; William M Brooks; Clifford Qualls; Roger Hammond; Blaine Hart; John Lauriello
Journal:  Neuropsychopharmacology       Date:  2007-12-19       Impact factor: 7.853

9.  Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia.

Authors:  Jean Théberge; Kate E Williamson; Naoko Aoyama; Dick J Drost; Rahul Manchanda; Ashok K Malla; Sandra Northcott; Ravi S Menon; Richard W J Neufeld; Nagalingam Rajakumar; William Pavlosky; Maria Densmore; Betsy Schaefer; Peter C Williamson
Journal:  Br J Psychiatry       Date:  2007-10       Impact factor: 9.319

10.  Brain metabolite abnormalities in the white matter of elderly schizophrenic subjects: implication for glial dysfunction.

Authors:  Linda Chang; Joseph Friedman; Thomas Ernst; Kai Zhong; Nicholas D Tsopelas; Kenneth Davis
Journal:  Biol Psychiatry       Date:  2007-08-13       Impact factor: 13.382

View more
  75 in total

Review 1.  Translating glutamate: from pathophysiology to treatment.

Authors:  Daniel C Javitt; Darryle Schoepp; Peter W Kalivas; Nora D Volkow; Carlos Zarate; Kalpana Merchant; Mark F Bear; Daniel Umbricht; Mihaly Hajos; William Z Potter; Chi-Ming Lee
Journal:  Sci Transl Med       Date:  2011-09-28       Impact factor: 17.956

2.  A combined diffusion tensor imaging and magnetic resonance spectroscopy study of patients with schizophrenia.

Authors:  Meredith A Reid; David M White; Nina V Kraguljac; Adrienne C Lahti
Journal:  Schizophr Res       Date:  2015-12-21       Impact factor: 4.939

3.  Reduced frontal glutamate + glutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia.

Authors:  Tatsunobu Natsubori; Hideyuki Inoue; Osamu Abe; Yosuke Takano; Norichika Iwashiro; Yuta Aoki; Shinsuke Koike; Noriaki Yahata; Masaki Katsura; Wataru Gonoi; Hiroki Sasaki; Hidemasa Takao; Kiyoto Kasai; Hidenori Yamasue
Journal:  Schizophr Bull       Date:  2013-09-10       Impact factor: 9.306

4.  Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla.

Authors:  Juan R Bustillo; Hongji Chen; Charles Gasparovic; Paul Mullins; Arvind Caprihan; Clifford Qualls; William Apfeldorf; John Lauriello; Stefan Posse
Journal:  Biol Psychiatry       Date:  2010-10-20       Impact factor: 13.382

Review 5.  Neurometabolites in schizophrenia and bipolar disorder - a systematic review and meta-analysis.

Authors:  Nina Vanessa Kraguljac; Meredith Reid; David White; Rebecca Jones; Jan den Hollander; Deborah Lowman; Adrienne Carol Lahti
Journal:  Psychiatry Res       Date:  2012-09-13       Impact factor: 3.222

6.  Prefrontal and Striatal Gamma-Aminobutyric Acid Levels and the Effect of Antipsychotic Treatment in First-Episode Psychosis Patients.

Authors:  Camilo de la Fuente-Sandoval; Francisco Reyes-Madrigal; Xiangling Mao; Pablo León-Ortiz; Oscar Rodríguez-Mayoral; Helgi Jung-Cook; Rodolfo Solís-Vivanco; Ariel Graff-Guerrero; Dikoma C Shungu
Journal:  Biol Psychiatry       Date:  2017-10-10       Impact factor: 13.382

7.  Age-related changes in anterior cingulate cortex glutamate in schizophrenia: A (1)H MRS Study at 7 Tesla.

Authors:  Allison S Brandt; Paul G Unschuld; Subechhya Pradhan; Issel Anne L Lim; Gregory Churchill; Ashley D Harris; Jun Hua; Peter B Barker; Christopher A Ross; Peter C M van Zijl; Richard A E Edden; Russell L Margolis
Journal:  Schizophr Res       Date:  2016-02-28       Impact factor: 4.939

8.  Regional decoupling of N-acetyl-aspartate and glutamate in schizophrenia.

Authors:  Nina V Kraguljac; Meredith A Reid; David M White; Jan den Hollander; Adrienne C Lahti
Journal:  Neuropsychopharmacology       Date:  2012-07-18       Impact factor: 7.853

Review 9.  Neurodegenerative aspects in vulnerability to schizophrenia spectrum disorders.

Authors:  Trevor Archer; Serafino Ricci; Danilo Garcia; Max Rapp Ricciardi
Journal:  Neurotox Res       Date:  2014-05-08       Impact factor: 3.911

10.  Altered Glutamate and Regional Cerebral Blood Flow Levels in Schizophrenia: A 1H-MRS and pCASL study.

Authors:  S Andrea Wijtenburg; Susan N Wright; Stephanie A Korenic; Frank E Gaston; Nkemdilim Ndubuizu; Joshua Chiappelli; Robert P McMahon; Hongji Chen; Anya Savransky; Xiaoming Du; Danny J J Wang; Peter Kochunov; L Elliot Hong; Laura M Rowland
Journal:  Neuropsychopharmacology       Date:  2016-08-26       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.